20, n o 11, 25652573 (ISSN 1462-8902 et 1463-1326, PMID 29893488, PMCID 6221089, DOI 10.1111/dom.13422, lire en ligne, consult le 1 2 (en) Ruth E Brown, Peter G Bech et Ronnie Aronson, Semaglutide once weekly in people with type 2 diabetes: Realworld analysis of the Canadian LMC diabetes registry ( SPARE study) , Diabetes, Obesity and Metabolism , vol
Australia's drug regulator has issued a safety alert about unregulated peptides, warning the latest wellness craze poses a "significant" public health risk
Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT)
The safety profile of GLP-1 medications as a class is well established
Determination of Reduced (GSH) and Oxidized (GSSG) Glutathione Plant tissue extraction and analyses of GSH and GSSG were carried out as described by Relln-lvarez et al